In contrast, experimental studies have shown that MR antagonism provides a hepatoprotective effect against steatosis and fibrosis in NASH, which underscores the role of MR in promoting the development and progression of MASLD (84, 85). The gene discussed is NR3C2; the disease is steatosis.